Strong half for Evotec as revenue jumps thanks to Big Pharma collabs

Evotec has posted a 37% sales jump in the first half of 2016 with its income bumped up to €75.7 million ($84.1 million) as it reaps the benefits of its collabs as well as its core business.

The German company, which is a hybrid CRO-cum-drug discovery firm, also saw its research receipts grow for the first half, up by 6% to €9 million as it ramps up the projects in its portfolio.

A fair chunk of its growth came from hitting a number of R&D milestones in the year, including those with Bayer, Boehringer Ingelheim and Padlock (now owned by Bristol-Myers Squibb [$BMY]).

Infographic Download

Reducing Time to Clinic for Your Biomedical Applications

Gelatin methacryloyl (GelMA)-based biomaterials have been widely used in various biomedical research applications due to their suitable biological properties and tunable physical characteristics. Especially over the past 5 years, GelMA-oriented research and patent applications have been growing exponentially, and many of these research concepts are now being translated towards the clinic. Suitable GelMA biomaterials are therefore indispensable to keep pace with the newest medical innovations.

Download to learn more about the benefits of GelMA in various biomedical applications and how X-Pure® GelMA can help you in your developments.

But even when these milestones, upfronts and licenses are taken out of the mix, Evotec's base revenues still hit €68.5 million, an increase of 35% over the same period of the previous year.

EVT Execute, Evotec's CRO division, also saw sales reach €79.8 million in the first half--an increase of 35% compared with 2015 figures.

The company has also signed a number of new deals over the past few months, including with a U.K. antibiotics group to help reverse resistance to older meds, as well as signing a pact to gain access to the hot ticket CRISPR tech.

It also launched its first spinoff, Topas Therapeutics GmbH, that will specialize in the field of nanoparticle-based therapeutics to treat immunological disorders.

- check out the release

Related Articles:
Evotec evolves as it announces first-ever spinoff and new business model
Evotec posts 50% growth with a big year in sight

Read more on

Suggested Articles

CTI Clinical Trial and Consulting Services is buying up fellow CRO Clinart to deepen its reach in the Middle Eastern and Northern African regions.

Viva Biotech is putting down $80 million to buy preclinical contract research organization SYNthesis and boost its outsourcing business.

Popular research network provider TriNetX has seen major interest from The Carlyle Group as it buys up a majority stake in the company.